{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:34:41Z","timestamp":1791840881158,"version":"4.3.4"},"reference-count":361,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012802","name":"Harvard University MIT Phillip T and Susan M Ragon Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012802","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.addr.2021.05.013","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T23:35:00Z","timestamp":1622244900000},"page":"113803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":189,"special_numbering":"C","title":["Evolution of Toll-like receptor 7\/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants"],"prefix":"10.1016","volume":"175","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4410-5800","authenticated-orcid":false,"given":"Sachin","family":"Bhagchandani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-6491","authenticated-orcid":false,"given":"Jeremiah A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell J.","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2021.05.013_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0192-0561(98)00068-X","article-title":"Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug","volume":"21","author":"Miller","year":"1999","journal-title":"Int. J. Immunopharmaco."},{"key":"10.1016\/j.addr.2021.05.013_b0010","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nri3446","article-title":"The history of Toll-like receptors \u2014 redefining innate immunity","volume":"13","author":"O\u2019Neill","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0015","unstructured":"J.F. Gerster, 1H-imidazo[4,5-c]quinolin-4-amines and antiviral use, 4,689,338, 1987. https:\/\/patentimages.storage.googleapis.com\/f3\/d6\/dd\/f2177153a97ae4\/US4689338.pdf."},{"key":"10.1016\/j.addr.2021.05.013_b0020","first-page":"CMT.S1969","article-title":"A review of topical imiquimod in the management of basal cell carcinoma, actinic keratoses, and other skin lesions","volume":"1","author":"Ryu","year":"2009","journal-title":"Clin. Med. Ther."},{"key":"10.1016\/j.addr.2021.05.013_b0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0166-3542(95)00054-P","article-title":"Immunomodulating and antiviral activities of the imidazoquinoline S-28463","volume":"28","author":"Tomai","year":"1995","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2021.05.013_b0030","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1021\/jm0203581","article-title":"Discovery of 8-hydroxyadenines as a novel type of interferon inducer","volume":"45","author":"Hirota","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b0035","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/jac\/48.6.751","article-title":"Imiquimod and resiquimod as novel immunomodulators","volume":"48","author":"Dockrell","year":"2001","journal-title":"J. Antimicrob. Chemoth."},{"key":"10.1016\/j.addr.2021.05.013_b0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.antiviral.2004.07.002","article-title":"Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses","volume":"64","author":"Wu","year":"2004","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2021.05.013_b0045","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2133.2008.08615.x","article-title":"A phase II dose-ranging study of topical resiquimod to treat actinic keratosis","volume":"159","author":"Szeimies","year":"2008","journal-title":"Brit. J. Dermatol."},{"key":"10.1016\/j.addr.2021.05.013_b0050","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fonc.2019.00260","article-title":"Skin directed therapy in cutaneous T-cell lymphoma","volume":"9","author":"Tarabadkar","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.addr.2021.05.013_b0055","doi-asserted-by":"crossref","DOI":"10.1038\/ni758","article-title":"Small anti-viral compounds activate immune cells via the TLR7 MyD88\u2013dependent signaling pathway","volume":"3","author":"Hemmi","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0060","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.smim.2006.12.004","article-title":"TLR signaling","volume":"19","author":"Kawai","year":"2007","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0065","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/jir.2007.0097","article-title":"TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN","volume":"28","author":"Inglefield","year":"2008","journal-title":"J. Interf. Cytokine Res. Off. J. Int. Soc. Interf. Cytokine Res."},{"key":"10.1016\/j.addr.2021.05.013_b0070","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1600-065X.2008.00604.x","article-title":"Twelve immunotherapy drugs that could cure cancers","volume":"222","author":"Cheever","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.addr.2021.05.013_b0075","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1586\/ecp.11.5","article-title":"The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system","volume":"4","author":"Engel","year":"2014","journal-title":"Expert Rev. Clin. Phar."},{"key":"10.1016\/j.addr.2021.05.013_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/2180417","article-title":"Holding the inflammatory system in check: TLRs and their targeted therapy in asthma","volume":"2016","author":"Dong","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.addr.2021.05.013_b0085","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/med.21553","article-title":"Recent clinical trends in Toll-like receptor targeting therapeutics","volume":"39","author":"Anwar","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.addr.2021.05.013_b0090","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/35100529","article-title":"Toll-like receptors and innate immunity","volume":"1","author":"Medzhitov","year":"2001","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0095","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.sbi.2017.05.010","article-title":"Structural insights into ligand recognition and regulation of nucleic acid-sensing Toll-like receptors","volume":"47","author":"Shimizu","year":"2017","journal-title":"Curr. Opin. Struc. Biol."},{"key":"10.1016\/j.addr.2021.05.013_b0100","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.immuni.2016.08.010","article-title":"K + efflux-independent NLRP3 inflammasome activation by small molecules targeting mitochondria","volume":"45","author":"Gro\u00df","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2021.05.013_b0105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.addr.2017.05.011","article-title":"Delivering safer immunotherapies for cancer","volume":"114","author":"Milling","year":"2017","journal-title":"Adv. Drug Deliver Rev."},{"key":"10.1016\/j.addr.2021.05.013_b0110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev.immunol.21.120601.141126","article-title":"Toll-like receptors","volume":"21","author":"Takeda","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0115","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1126\/science.1093616","article-title":"Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA","volume":"303","author":"Diebold","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.05.013_b0120","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.05.013_b0125","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.addr.2021.05.013_b0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrg2303","article-title":"Toll-like receptors \u2014 taking an evolutionary approach","volume":"9","author":"Leulier","year":"2008","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.addr.2021.05.013_b0135","doi-asserted-by":"crossref","DOI":"10.1038\/90609","article-title":"Toll-like receptors: critical proteins linking innate and acquired immunity","volume":"2","author":"Akira","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0140","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0968-0004(02)02145-X","article-title":"A universal role for MyD88 in TLR\/IL-1R-mediated signaling","volume":"27","author":"Janssens","year":"2002","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.addr.2021.05.013_b0145","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1084\/jem.20061523","article-title":"Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor\u2013mediated immune responses but not in TCR signaling","volume":"204","author":"Kawagoe","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.addr.2021.05.013_b0150","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/sj.cdd.4401850","article-title":"TLR signaling","volume":"13","author":"Kawai","year":"2006","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.addr.2021.05.013_b0155","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/nri3713","article-title":"Assembly and localization of Toll-like receptor signalling complexes","volume":"14","author":"Gay","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0160","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0165","doi-asserted-by":"crossref","DOI":"10.1038\/nri1625","article-title":"Intracellular trafficking, IRF7 and type-I-IFN responses","volume":"5","author":"Bell","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0170","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.4049\/jimmunol.168.9.4531","article-title":"Quantitative expression of toll-like receptor 1\u201310 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides","volume":"168","author":"Hornung","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0175","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ni1112","article-title":"Toll-like receptor control of the adaptive immune responses","volume":"5","author":"Iwasaki","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.smim.2003.10.004","article-title":"Toll-like receptors and dendritic cells: for whom the bug tolls","volume":"16","author":"e Sousa","year":"2004","journal-title":"Sem. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0185","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/ni.3123","article-title":"Control of adaptive immunity by the innate immune system","volume":"16","author":"Iwasaki","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0190","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nri2038","article-title":"Cooperation of Toll-like receptor signals in innate immune defence","volume":"7","author":"Trinchieri","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0195","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3389\/fimmu.2017.01075","article-title":"The toll for trafficking: toll-like receptor 7 delivery to the endosome","volume":"8","author":"Petes","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0200","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev-immunol-020711-074950","article-title":"The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting","volume":"31","author":"Merad","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0205","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1189\/jlb.0808504","article-title":"TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation","volume":"85","author":"Larang\u00e9","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.addr.2021.05.013_b0210","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/eji.200323797","article-title":"Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8\u03b1+ DC correlates with unresponsiveness to imidazoquinolines","volume":"33","author":"Edwards","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0215","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.vetimm.2008.05.001","article-title":"Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates","volume":"125","author":"Ketloy","year":"2008","journal-title":"Vet. Immunol. Immunop."},{"key":"10.1016\/j.addr.2021.05.013_b0220","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4049\/jimmunol.171.3.1156","article-title":"The immune response modifier and toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-\u03b1 production in CD11c+CD11b+CD8\u2212 dendritic cells","volume":"171","author":"Doxsee","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0225","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nri.2016.116","article-title":"Dendritic cell migration in health and disease","volume":"17","author":"Worbs","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0230","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/nri1246","article-title":"Dendritic-cell control of pathogen-driven T-cell polarization","volume":"3","author":"Kapsenberg","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0235","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1006\/cimm.1998.1406","article-title":"Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod","volume":"191","author":"Wagner","year":"1999","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0240","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1126\/science.1113401","article-title":"Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function","volume":"309","author":"Peng","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.05.013_b0245","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coi.2006.11.007","article-title":"Expression and function of Toll-like receptors in T lymphocytes","volume":"19","author":"Kabelitz","year":"2007","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0250","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1074-7613(00)80197-1","article-title":"Antigen-specific regulation of T cell-mediated cytokine production","volume":"12","author":"Slifka","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2021.05.013_b0255","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2796.2008.02050.x","article-title":"Signalling pathways leading to IFN-\u03b1 production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications","volume":"265","author":"Guiducci","year":"2009","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.addr.2021.05.013_b0260","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.onc.1210911","article-title":"Toll-like receptor 9 (TLR9) agonists in the treatment of cancer","volume":"27","author":"Krieg","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.addr.2021.05.013_b0265","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.tcb.2020.01.010","article-title":"Structural insights into STING signaling","volume":"30","author":"Ergun","year":"2020","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.addr.2021.05.013_b0270","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/cdd.2016.24","article-title":"Ly6C+ monocyte efferocytosis and cross-presentation of cell-associated antigens","volume":"23","author":"Larson","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.addr.2021.05.013_b0275","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jaci.2009.02.015","article-title":"Selective and direct activation of human neutrophils but not eosinophils by Toll-like receptor 8","volume":"123","author":"Janke","year":"2009","journal-title":"J. Allergy Clin. Immun."},{"key":"10.1016\/j.addr.2021.05.013_b0280","doi-asserted-by":"crossref","first-page":"107746","DOI":"10.1016\/j.celrep.2020.107746","article-title":"TLR7 sensing by neutrophils is critical for the control of cutaneous leishmaniasis","volume":"31","author":"Regli","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2021.05.013_b0285","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4049\/jimmunol.173.1.531","article-title":"TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells","volume":"173","author":"Matsushima","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0290","doi-asserted-by":"crossref","DOI":"10.1152\/ajpregu.00527.2007","article-title":"Mast cell-dependent anorexia and hypothermia induced by mucosal activation of Toll-like receptor 7","volume":"295","author":"Hayashi","year":"2008","journal-title":"Am. J. Physiol.-Regul. Integ. Comp. Physiol."},{"key":"10.1016\/j.addr.2021.05.013_b0295","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.4049\/jimmunol.171.8.3977","article-title":"Expression and function of toll-like receptors in eosinophils: activation by toll-like receptor 7 ligand","volume":"171","author":"Nagase","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0300","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/1078-0432.CCR-09-2591","article-title":"Reciprocal regulation of activating and inhibitory Fc\u03b3 receptors by TLR7\/8 activation: implications for tumor immunotherapy","volume":"16","author":"Butchar","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2021.05.013_b0305","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/intimm\/dxf069","article-title":"Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines","volume":"14","author":"Applequist","year":"2002","journal-title":"Int. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0310","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1182\/blood-2003-04-1078","article-title":"Toll-like receptors stimulate human neutrophil function","volume":"102","author":"Hayashi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.addr.2021.05.013_b0315","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1182\/blood-2008-01-132860","article-title":"Toll-like receptor\u2013mediated activation of neutrophils by influenza A virus","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.addr.2021.05.013_b0320","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.immuni.2008.05.016","article-title":"Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms","volume":"29","author":"Hou","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2021.05.013_b0325","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms5674","article-title":"Dendritic cell subsets require cis-activation for cytotoxic CD8 T-cell induction","volume":"5","author":"Desch","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2021.05.013_b0330","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ni1162","article-title":"Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function","volume":"6","author":"Sp\u00f6rri","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0335","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1182\/blood-2008-03-146290","article-title":"Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation","volume":"112","author":"Mouri\u00e8s","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.addr.2021.05.013_b0340","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.4049\/jimmunol.165.10.5552","article-title":"Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848","volume":"165","author":"Bishop","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0345","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2567.2011.03484.x","article-title":"Human and rhesus plasmacytoid dendritic cell and B-cell responses to Toll-like receptor stimulation","volume":"134","author":"Gujer","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.addr.2021.05.013_b0350","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/1753425916651985","article-title":"Distinct TLR-mediated cytokine production and immunoglobulin secretion in human newborn na\u00efve B cells","volume":"22","author":"Pettengill","year":"2016","journal-title":"Innate Immun."},{"key":"10.1016\/j.addr.2021.05.013_b0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000863","article-title":"Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets","volume":"2","author":"Gururajan","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2021.05.013_b0360","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1006\/cimm.2001.1769","article-title":"The immune response modifier resiquimod mimics CD40-induced B cell activation","volume":"208","author":"Bishop","year":"2001","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0365","doi-asserted-by":"crossref","first-page":"e0166322","DOI":"10.1371\/journal.pone.0166322","article-title":"T cell production of IFN\u03b3 in response to TLR7\/IL-12 stimulates optimal B cell responses to viruses","volume":"11","author":"Rubtsova","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2021.05.013_b0370","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1126\/science.1229159","article-title":"Structural reorganization of the toll-like receptor 8 dimer induced by agonistic ligands","volume":"339","author":"Tanji","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.05.013_b0375","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.immuni.2016.09.011","article-title":"Structural analysis reveals that toll-like receptor 7 is a dual receptor for guanosine and single-stranded RNA","volume":"45","author":"Zhang","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2021.05.013_b0380","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1021\/jm049211v","article-title":"Synthesis and structure\u2212activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production","volume":"48","author":"Gerster","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b0385","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/jm100358c","article-title":"Structure\u2212activity relationships in human toll-like receptor 7-active imidazoquinoline analogues","volume":"53","author":"Shukla","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b0390","doi-asserted-by":"crossref","first-page":"e0134640","DOI":"10.1371\/journal.pone.0134640","article-title":"The imidazoquinoline toll-like receptor-7\/8 agonist hybrid-2 potently induces cytokine production by human newborn and adult leukocytes","volume":"10","author":"Ganapathi","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2021.05.013_b0395","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1021\/ml300079e","article-title":"Discovery of imidazoquinolines with toll-like receptor 7\/8 independent cytokine induction","volume":"3","author":"Shi","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.addr.2021.05.013_b0400","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1021\/jm4004957","article-title":"Structure-activity relationship analysis of imidazoquinolines with toll-like receptors 7 and 8 selectivity and enhanced cytokine induction","volume":"57","author":"Schiaffo","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b0405","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1021\/acsmedchemlett.7b00256","article-title":"Design and synthesis of N1-modified imidazoquinoline agonists for selective activation of toll-like receptors 7 and 8","volume":"8","author":"Larson","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.addr.2021.05.013_b0410","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1021\/acs.jmedchem.5b01087","article-title":"Structure-based design of human TLR8-specific agonists with augmented potency and adjuvanticity","volume":"58","author":"Beesu","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b0415","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1021\/jm2010207","article-title":"Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines","volume":"55","author":"Shukla","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b0420","doi-asserted-by":"crossref","first-page":"e43612","DOI":"10.1371\/journal.pone.0043612","article-title":"Potent adjuvanticity of a pure TLR7-agonistic imidazoquinoline dendrimer","volume":"7","author":"Shukla","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2021.05.013_b0425","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.1039\/c3ob40816g","article-title":"Structure\u2013activity relationships in Toll-like receptor 7 agonistic 1H-imidazo[4,5-c]pyridines","volume":"11","author":"Yoo","year":"2013","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b0430","doi-asserted-by":"crossref","first-page":"7955","DOI":"10.1021\/jm500744f","article-title":"Determinants of activity at human toll-like receptors 7 and 8: quantitative structure-activity relationship (QSAR) of diverse heterocyclic scaffolds","volume":"57","author":"Yoo","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b0435","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1039\/c2ob26705e","article-title":"Toll-like receptor-8 agonistic activities in C2, C4, and C8 modified thiazolo[4,5-c]quinolines","volume":"11","author":"Kokatla","year":"2013","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b0440","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1021\/acs.jmedchem.6b01860","article-title":"Identification of high-potency human TLR8 and dual TLR7\/TLR8 agonists in pyrimidine-2,4-diamines","volume":"60","author":"Beesu","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b0445","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4043","article-title":"Structural and functional understanding of the Toll-like receptors","author":"Asami","year":"2021","journal-title":"Protein Sci."},{"key":"10.1016\/j.addr.2021.05.013_b0450","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1016\/j.celrep.2018.11.081","article-title":"Structural analyses of toll-like receptor 7 reveal detailed RNA sequence specificity and recognition mechanism of agonistic ligands","volume":"25","author":"Zhang","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2021.05.013_b0455","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1189\/jlb.4MR0316-108R","article-title":"Emerging roles of the processing of nucleic acids and Toll-like receptors in innate immune responses to nucleic acids","volume":"101","author":"Miyake","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.addr.2021.05.013_b0460","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.immuni.2016.10.003","article-title":"TLR7 structure: cut in Z-loop","volume":"45","author":"Maeda","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2021.05.013_b0465","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1107\/S2059798320006518","article-title":"Targeting the innate immune receptor TLR8 using small-molecule agents","volume":"76","author":"Sakaniwa","year":"2020","journal-title":"Acta Crystallogr. Sect. D Struct. Biol."},{"key":"10.1016\/j.addr.2021.05.013_b0470","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1021\/jm051089s","article-title":"Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers","volume":"49","author":"Isobe","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b0475","doi-asserted-by":"crossref","first-page":"7324","DOI":"10.1021\/jm400815m","article-title":"Identification and optimization of pteridinone toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis","volume":"56","author":"Roethle","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b0480","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.2174\/1568026619666191009165418","article-title":"Latest advances in small molecule TLR 7\/8 agonist drug research","volume":"19","author":"McGowan","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b0485","doi-asserted-by":"crossref","first-page":"112238","DOI":"10.1016\/j.ejmech.2020.112238","article-title":"Agonist and antagonist ligands of toll-like receptors 7 and 8: ingenious tools for therapeutic purposes","volume":"193","author":"Patinote","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b0490","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1021\/acs.accounts.9b00631","article-title":"Small-molecule modulators of toll-like receptors","volume":"53","author":"Wang","year":"2020","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.addr.2021.05.013_b0495","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1248\/cpb.52.466","article-title":"Prodrugs of 9-benzyl-8-hydroxy-2-(2-hydroxyethylthio)adenine: potent interferon inducing agents in monkeys","volume":"52","author":"Kurimoto","year":"2004","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.addr.2021.05.013_b0500","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bmcl.2012.11.114","article-title":"Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility","volume":"23","author":"Nakamura","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.addr.2021.05.013_b0505","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1002\/eji.200324238","article-title":"The toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily","volume":"33","author":"Heil","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0510","doi-asserted-by":"crossref","first-page":"15665","DOI":"10.1021\/acsomega.9b02138","article-title":"Synthetic toll-like receptors 7 and 8 agonists: structure-activity relationship in the oxoadenine series","volume":"4","author":"Evans","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.addr.2021.05.013_b0515","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.bmcl.2015.01.037","article-title":"Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives","volume":"25","author":"Bazin","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.addr.2021.05.013_b0520","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/j.bmcl.2009.02.095","article-title":"2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation","volume":"19","author":"Weterings","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.addr.2021.05.013_b0525","doi-asserted-by":"crossref","first-page":"e56514","DOI":"10.1371\/journal.pone.0056514","article-title":"Toll-Like Receptor 7 Agonists: Chemical Feature Based Pharmacophore Identification and Molecular Docking Studies","volume":"8","author":"Yu","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2021.05.013_b0530","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/09546630802513693","article-title":"A pharmaceutical comparison of different commercially available imiquimod 5% cream products","volume":"20","author":"Harrison","year":"2009","journal-title":"J Dermatol Treat."},{"key":"10.1016\/j.addr.2021.05.013_b0535","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10837459908984222","article-title":"Development of a Topically Active Imiquimod Formulation","volume":"4","author":"Chollet","year":"1999","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.addr.2021.05.013_b0540","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.0366-077X.2003.05628.x","article-title":"Imiquimod: modes of action","volume":"149","author":"Sauder","year":"2003","journal-title":"Brit J Dermatol."},{"key":"10.1016\/j.addr.2021.05.013_b0545","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral Actions of Interferons","volume":"14","author":"Samuel","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.addr.2021.05.013_b0550","doi-asserted-by":"crossref","first-page":"12720","DOI":"10.1128\/JVI.01471-07","article-title":"Viral Encounters with 2\u2032,5\u2032-Oligoadenylate Synthetase and RNase L during the Interferon Antiviral Response","volume":"81","author":"Silverman","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.05.013_b0555","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.4049\/jimmunol.173.5.3051","article-title":"Identification and Characterization of pDC-Like Cells in Normal Mouse Skin and Melanomas Treated with Imiquimod","volume":"173","author":"Palamara","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0560","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2174\/138955706776876131","article-title":"Topical Imiquimod: Mechanism of Action and Clinical Applications","volume":"6","author":"Vidal","year":"2006","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b0565","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1089\/jir.2009.0075","article-title":"Human papillomaviruses and the interferon response","volume":"29","author":"Beglin","year":"2009","journal-title":"J Interf Cytokine Res Official J Int Soc Interf Cytokine Res."},{"key":"10.1016\/j.addr.2021.05.013_b0570","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.1067\/mjd.2002.126586","article-title":"Imiquimod: A cytokine inducer","volume":"47","author":"Dahl","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2021.05.013_b0575","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1523-1747.2000.00833.x","article-title":"Imiquimod, a Topical Immune Response Modifier, Induces Migration of Langerhans Cells 1 1 The authors have declared a conflict of interest","volume":"114","author":"Suzuki","year":"2000","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.addr.2021.05.013_b0580","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00003495-199958020-00017","article-title":"Topical Imiquimod: A Review of its Use in Genital Warts","volume":"58","author":"Perry","year":"1999","journal-title":"Drugs."},{"key":"10.1016\/j.addr.2021.05.013_b0585","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/archderm.134.1.25","article-title":"Self-administered Topical 5% Imiquimod Cream for External Anogenital Warts","volume":"134","author":"Edwards","year":"1998","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.addr.2021.05.013_b0590","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/1346-8138.12969","article-title":"Successful treatment of hypertrophic herpes simplex genitalis in HIV-infected patient with topical imiquimod","volume":"42","author":"Deza","year":"2015","journal-title":"J Dermatology."},{"key":"10.1016\/j.addr.2021.05.013_b0595","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0166-3542(99)00052-2","article-title":"Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod","volume":"44","author":"Miller","year":"1999","journal-title":"Antivir Res."},{"key":"10.1016\/j.addr.2021.05.013_b0600","first-page":"3243","article-title":"Imiquimod 5-Percent Cream Does Not Alter the Natural History of Recurrent Herpes Genitalis: a Phase II","volume":"46","author":"Schacker","year":"2002","journal-title":"Randomized, Double-Blind, Placebo-Controlled Study, Antimicrob Agents Ch."},{"key":"10.1016\/j.addr.2021.05.013_b0605","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1158\/1078-0432.CCR-07-4760","article-title":"Clinical and Immunologic Results of a Phase II Trial of Sequential Imiquimod and Photodynamic Therapy for Vulval Intraepithelial Neoplasia","volume":"14","author":"Winters","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2021.05.013_b0610","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/sj.bjc.6605611","article-title":"Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia","volume":"102","author":"Daayana","year":"2010","journal-title":"Brit J Cancer."},{"key":"10.1016\/j.addr.2021.05.013_b0615","article-title":"Systemic adverse events in imiquimod use for cervical intraepithelial neoplasia \u2013 A case series","volume":"21","author":"Wouters","year":"2019","journal-title":"Case Reports Women\u2019s Heal."},{"key":"10.1016\/j.addr.2021.05.013_b0620","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/sj.jid.5700264","article-title":"Imiquimod for Actinic Keratosis: Systematic Review and Meta-Analysis","volume":"126","author":"Hadley","year":"2006","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.addr.2021.05.013_b0625","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/CIA.S31930","article-title":"Optimal treatment of actinic keratoses","volume":"8","author":"Uhlenhake","year":"2013","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.addr.2021.05.013_b0630","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2003.12.010","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials","volume":"50","author":"Lebwohl","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2021.05.013_b0635","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jaad.2003.11.066","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies","volume":"50","author":"Geisse","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2021.05.013_b0640","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3816\/CLM.2007.n.037","article-title":"Synthetic Imidazoquinolines Potently and Broadly Activate the Cellular Immune Response of Patients with Cutaneous T-Cell Lymphoma: Synergy with Interferon-\u03b3 Enhances Production of Interleukin-12","volume":"7","author":"Wysocka","year":"2007","journal-title":"Clin Lymphoma Myeloma."},{"key":"10.1016\/j.addr.2021.05.013_b0645","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archderm.138.9.1137","article-title":"Treatment of Stage IA Cutaneous T-Cell Lymphoma With Topical Application of the Immune Response Modifier Imiquimod","volume":"138","author":"Suchin","year":"2002","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.addr.2021.05.013_b0650","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","article-title":"Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma","volume":"126","author":"Rook","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.addr.2021.05.013_b0655","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/archderm.139.3.273","article-title":"Topical Imiquimod in the Treatment of Metastatic Melanoma to Skin","volume":"139","author":"Wolf","year":"2003","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.addr.2021.05.013_b0660","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/jid.2011.247","article-title":"Immunomodulation by imiquimod in patients with high-risk primary melanoma","volume":"132","author":"Narayan","year":"2011","journal-title":"J Investigative Dermatology."},{"key":"10.1016\/j.addr.2021.05.013_b0665","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1158\/1078-0432.CCR-12-1149","article-title":"Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer","volume":"18","author":"Adams","year":"2012","journal-title":"Clin Cancer Res Official J Am Assoc Cancer Res."},{"key":"10.1016\/j.addr.2021.05.013_b0670","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1016\/j.jaad.2004.10.858","article-title":"Topical application of imiquimod and associated fever in children","volume":"52","author":"Campanelli","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2021.05.013_b0675","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1111\/j.1365-2230.2008.03181.x","article-title":"Pemphigus-like lesions induced by imiquimod","volume":"34","author":"Bauza","year":"2009","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.addr.2021.05.013_b0680","doi-asserted-by":"crossref","DOI":"10.1136\/sextrans-2011-050025","article-title":"Local and systemic adverse effects to topical imiquimod due to systemic immune stimulation","volume":"87","author":"Kumar","year":"2011","journal-title":"Sex Transm Infect."},{"key":"10.1016\/j.addr.2021.05.013_b0685","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","article-title":"Interferons \u03b1 and \u03b2 in cancer: therapeutic opportunities from new insights","volume":"18","author":"Borden","year":"2019","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.addr.2021.05.013_b0690","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fphar.2017.00304","article-title":"Anti-tumor Activity of Toll-Like Receptor 7 Agonists","volume":"8","author":"Chi","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2021.05.013_b0695","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/djg016","article-title":"Tumor-Selective Induction of Apoptosis and the Small-Molecule Immune Response Modifier Imiquimod","volume":"95","author":"Schon","year":"2003","journal-title":"Jnci J National Cancer Inst."},{"key":"10.1016\/j.addr.2021.05.013_b0700","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jdermsci.2015.12.011","article-title":"Imiquimod activates p53-dependent apoptosis in a human basal cell carcinoma cell line","volume":"81","author":"Huang","year":"2015","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.addr.2021.05.013_b0705","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.991615","article-title":"Dual roles of TLR7 in the lung cancer microenvironment","volume":"4","author":"Dajon","year":"2015","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.addr.2021.05.013_b0710","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/sj.onc.1210913","article-title":"TLR7 and TLR8 as targets in cancer therapy","volume":"27","author":"Sch\u00f6n","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.addr.2021.05.013_b0715","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1634\/theoncologist.2008-0097","article-title":"The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy","volume":"13","author":"Smits","year":"2008","journal-title":"Oncol."},{"key":"10.1016\/j.addr.2021.05.013_b0720","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1177\/0091270007303766","article-title":"Pharmacokinetics of 852A, an Imidazoquinoline Toll-Like Receptor 7-Specific Agonist, Following Intravenous, Subcutaneous, and Oral Administrations in Humans","volume":"47","author":"Harrison","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2021.05.013_b0725","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1158\/1078-0432.CCR-07-1443","article-title":"First in Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer","volume":"13","author":"Dudek","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2021.05.013_b0730","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1158\/1078-0432.CCR-07-1938","article-title":"An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma","volume":"14","author":"Dummer","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"151","key":"10.1016\/j.addr.2021.05.013_b0735","first-page":"3007","article-title":"Loxoribine (7-allyl-8-oxoguanosine) activates natural killer cells and primes cytolytic precursor cells for activation by IL-2","volume":"1950","author":"Pope","year":"1993","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.addr.2021.05.013_b0740","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF01526202","article-title":"7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine","volume":"38","author":"Pope","year":"1994","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.addr.2021.05.013_b0745","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/mccm.6.4.171.176","article-title":"Phase I, Randomized, Double-blind Trial of 7-allyl-8-oxoguanosine (Loxoribine) in Advanced Cancer","volume":"6","author":"Agarwala","year":"2009","journal-title":"Cytokines Cell Mol Ther."},{"key":"10.1016\/j.addr.2021.05.013_b0750","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/ijc.28711","article-title":"A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models","volume":"135","author":"Adlard","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2021.05.013_b0755","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0140-6736(09)60404-9","article-title":"Use of tumour-responsive T cells as cancer treatment","volume":"373","author":"Disis","year":"2009","journal-title":"Lancet Lond Engl."},{"key":"10.1016\/j.addr.2021.05.013_b0760","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fimmu.2018.00014","article-title":"Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy","volume":"9","author":"Durgeau","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0765","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fimmu.2014.00083","article-title":"TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects","volume":"5","author":"Lu","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0770","doi-asserted-by":"crossref","unstructured":"Y. Ota, T. Otsubo, J. Koroki, Y. Hirose, E. Koga-Yamakawa, M. Murata, M. Goto, Y. Matsuki, Abstract 4726: Novel intravenous injectable TLR7 agonist, DSP-0509, synergistically enhanced antitumor immune responses in combination with anti-PD-1 antibody, (2018) 4726\u20134726. https:\/\/doi.org\/10.1158\/1538-7445.am2018-4726.","DOI":"10.1158\/1538-7445.AM2018-4726"},{"key":"10.1016\/j.addr.2021.05.013_b0775","doi-asserted-by":"crossref","unstructured":"S.E. Ackerman, J.C. Gonzalez, J.D. Gregorio, J.C. Paik, F.J. Hartmann, J.A. Kenkel, A. Lee, A. Luo, C.I. Pearson, M.L. Nguyen, B. Ackerman, L.Y. Sheu, R.P. Laura, S.J. Chapin, B.S. Safina, S.C. Bendall, D. Dornan, E.G. Engleman, M.N. Alonso, Abstract 1559: TLR7\/8 immune-stimulating antibody conjugates elicit robust myeloid activation leading to enhanced effector function and anti-tumor immunity in pre-clinical models, (2019) 1559\u20131559. https:\/\/doi.org\/10.1158\/1538-7445.am2019-1559.","DOI":"10.1158\/1538-7445.AM2019-1559"},{"key":"10.1016\/j.addr.2021.05.013_b0780","first-page":"1","article-title":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity, Nat","author":"Ackerman","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2021.05.013_b0785","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.3110","article-title":"SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist","volume":"38","author":"Metz","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2021.05.013_b0790","doi-asserted-by":"crossref","unstructured":"K. Moyes, T. Brender, S.W. Smith, H. Xu, B. Setter, L.-Q. Fan, R. Brunette, J. Killebrew, P. Tan, C. Coburn, P. Baum, V. Odegard, Abstract 3271: A systemically administered, conditionally active TLR8 agonist for the treatment of HER2-expressing tumors, (2019) 3271\u20133271. https:\/\/doi.org\/10.1158\/1538-7445.am2019-3271.","DOI":"10.1158\/1538-7445.AM2019-3271"},{"key":"10.1016\/j.addr.2021.05.013_b0795","unstructured":"J. Tan, T. Harding, S. Fletcher, S. Fish, G. Haley, J. Lennox, E. Rueden, D.A. and J. Appleman, The active metabolite of the TLR7 agonist prodrug ANA773 activates anti-tumor activity by natural killer cells, Cancer Res. 67 (9 Supplement) (1AD) 3556. https:\/\/cancerres-aacrjournals-org.libproxy.mit.edu\/content\/67\/9_Supplement\/3556."},{"key":"10.1016\/j.addr.2021.05.013_b0800","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.2524","article-title":"Phase I open-label, dose-escalation study of ANA773 tosylate, an oral prodrug of a toll-like receptor-7 agonist, in patients with advanced solid tumors","volume":"29","author":"Daniels","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2021.05.013_b0805","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1159\/000020051","article-title":"Results of a European Comparative Randomized Study Comparing Oral Bropirimine versus Intravesical BCG Treatment in BCG-Naive Patients with Carcinoma in situ of the Urinary Bladder","volume":"36","author":"Witjes","year":"1999","journal-title":"Eur. Urol."},{"key":"10.1016\/j.addr.2021.05.013_b0810","doi-asserted-by":"crossref","unstructured":"J.R. Appleman, S.E. Webber, Pharmacodynamic response in vitro and in vivo of novel orally administered Toll-like Receptor 7 agonists for systemic immunotherapy of cancer, in: Pharmacodynamic Response in Vitro and in Vivo of Novel Orally Administered Toll-like Receptor 7 Agonists for Systemic Immunotherapy of Cancer, 2019.","DOI":"10.1158\/1538-7445.AM2019-3262"},{"key":"10.1016\/j.addr.2021.05.013_b0815","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/imm.12622","article-title":"Strategies for designing synthetic immune agonists","volume":"148","author":"Wu","year":"2016","journal-title":"Immunology"},{"key":"10.1016\/j.addr.2021.05.013_b0820","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1442-2042.2010.02503.x","article-title":"Intravesical Toll-like receptor 7 agonist R-837: Optimization of its formulation in an orthotopic mouse model of bladder cancer","volume":"17","author":"Hayashi","year":"2010","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.addr.2021.05.013_b0825","first-page":"204","article-title":"Pharmacokinetic, pharmacodynamic, and activity evaluation of TMX-101 in a multicenter phase 1 study in patients with papillary non-muscle-invasive bladder cancer","volume":"13","author":"Arends","year":"2015","journal-title":"Clin. Genitourin. Canc."},{"issue":"39","key":"10.1016\/j.addr.2021.05.013_b0830","first-page":"e1","article-title":"A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer","volume":"35","author":"Donin","year":"2017","journal-title":"Urologic Oncol. Sem. Orig. Invest."},{"key":"10.1016\/j.addr.2021.05.013_b0835","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1158\/1078-0432.CCR-14-0392","article-title":"A phase I dose-finding study of the novel toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma","volume":"20","author":"Northfelt","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2021.05.013_b0840","doi-asserted-by":"crossref","unstructured":"A. Facciabene, A. Malykhin, M. Mathews, C. Fang, G. Dietsch, R. Hershberg, G. Coukos, Abstract 4745: TLR8 agonist and Doxil chemotherapy potently activate human antitumor immune response in a human immune system mouse model, 2011, pp. 4745\u20134745. https:\/\/doi.org\/10.1158\/1538-7445.am2011-4745.","DOI":"10.1158\/1538-7445.AM2011-4745"},{"key":"10.1016\/j.addr.2021.05.013_b0845","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1158\/1078-0432.CCR-15-0578","article-title":"Late-stage cancer patients remain highly responsive to immune activation by the selective TLR8 agonist motolimod (VTX-2337)","volume":"21","author":"Dietsch","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2021.05.013_b0850","first-page":"4722","article-title":"Effective innate and adaptive antimelanoma immunity through localized TLR7\/8 activation","volume":"193","author":"Singh","year":"2014","journal-title":"J. Immunol. Baltim. Md. 1950"},{"key":"10.1016\/j.addr.2021.05.013_b0855","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41578-019-0156-6","article-title":"Materials for oral delivery of proteins and peptides","volume":"5","author":"Brown","year":"2019","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.addr.2021.05.013_b0860","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2217\/fvl.14.70","article-title":"Novel drugs targeting Toll-like receptors for antiviral therapy","volume":"9","author":"Patel","year":"2014","journal-title":"Future Virol."},{"key":"10.1016\/j.addr.2021.05.013_b0865","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/jac\/dkr588","article-title":"Antiviral applications of Toll-like receptor agonists","volume":"67","author":"Horscroft","year":"2012","journal-title":"J. Antimicrob. Chemoth."},{"key":"10.1016\/j.addr.2021.05.013_b0870","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/v5020470","article-title":"Learning from the messengers: innate sensing of viruses and cytokine regulation of immunity - clues for treatments and vaccines","volume":"5","author":"Melchjorsen","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.addr.2021.05.013_b0875","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jhep.2007.02.025","article-title":"Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies","volume":"47","author":"Pockros","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.addr.2021.05.013_b0880","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/clpt.2011.60","article-title":"The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691)","volume":"89","author":"Fidock","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2021.05.013_b0885","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/15257770701490472","article-title":"Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine","volume":"26","author":"Xiang","year":"2007","journal-title":"Nucl. Nucl. Nucl. Acids"},{"key":"10.1016\/j.addr.2021.05.013_b0890","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coviro.2018.01.008","article-title":"Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B","volume":"30","author":"Suslov","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.addr.2021.05.013_b0895","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1358\/dnp.2008.21.2.1188193","article-title":"The antiviral activity of toll-like receptor 7 and 7\/8 agonists","volume":"21","author":"Miller","year":"2008","journal-title":"Drug News Perspect."},{"key":"10.1016\/j.addr.2021.05.013_b0900","doi-asserted-by":"crossref","DOI":"10.1111\/cts.12791","article-title":"A Single and multiple ascending dose study of toll-like receptor 7 agonist (RO7020531) in Chinese healthy volunteers","author":"Luk","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.addr.2021.05.013_b0905","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13016","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers","author":"Grippo","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.addr.2021.05.013_b0910","article-title":"Safety, pharmacokinetics, and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist, in healthy individuals","author":"Zhang","year":"2021","journal-title":"Expert Opin. Inv. Drug."},{"key":"10.1016\/j.addr.2021.05.013_b0915","article-title":"O-015: Combination treatment of a TLR7 agonist RO7020531 and a capsid assembly modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV-HBV mouse model","volume":"25","author":"Gao","year":"2018","journal-title":"J. Viral Hepatitis"},{"key":"10.1016\/j.addr.2021.05.013_b0920","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1124\/jpet.113.207878","article-title":"Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses","volume":"348","author":"Fosdick","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2021.05.013_b0925","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection","volume":"63","author":"Gane","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.addr.2021.05.013_b0930","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2014.12.026","article-title":"Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B","volume":"62","author":"Menne","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.addr.2021.05.013_b0935","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2021.05.013_b0940","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep4.1397","article-title":"Liver-targeted toll-like receptor 7 agonist combined with entecavir promotes a functional cure in the woodchuck model of hepatitis B virus","volume":"3","author":"Korolowizc","year":"2019","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.addr.2021.05.013_b0945","doi-asserted-by":"crossref","first-page":"e1004210","DOI":"10.1371\/journal.ppat.1004210","article-title":"Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver","volume":"10","author":"Jo","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.addr.2021.05.013_b0950","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","article-title":"Viral clearance without destruction of infected cells during acute HBV infection","volume":"284","author":"Guidotti","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.05.013_b0955","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.0c00100","article-title":"Discovery of GS-9688 (Selgantolimod) as a potent and selective oral toll-like receptor 8 agonist for the treatment of chronic hepatitis B","author":"Mackman","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b0960","article-title":"Toll-like receptor 8 agonist GS-9688 induces sustained efficacy in the woodchuck model of chronic hepatitis B","author":"Daffis","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.addr.2021.05.013_b0965","doi-asserted-by":"crossref","first-page":"e01369","DOI":"10.1128\/AAC.01369-16","article-title":"TLR7 agonist GS-9620 is a potent inhibitor of acute HIV-1 infection in human peripheral blood mononuclear cells","volume":"61","author":"Bam","year":"2017","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.addr.2021.05.013_b0970","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nature20583","article-title":"Ad26\/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys","volume":"540","author":"Borducchi","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.05.013_b0975","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","volume":"563","author":"Borducchi","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.05.013_b0980","doi-asserted-by":"crossref","first-page":"eaao4521","DOI":"10.1126\/scitranslmed.aao4521","article-title":"TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy","volume":"10","author":"Lim","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2021.05.013_b0985","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4049\/jimmunol.1500530","article-title":"Bacterial RNA: an underestimated stimulus for innate immune responses","volume":"195","author":"Eigenbrod","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0990","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3389\/fimmu.2019.01209","article-title":"Human toll-like receptor 8 (TLR8) is an important sensor of pyogenic bacteria, and is attenuated by cell surface TLR signaling","volume":"10","author":"Moen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b0995","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/cmi.2012.38","article-title":"TLR8: the forgotten relative revindicated","volume":"9","author":"Cervantes","year":"2012","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b1000","doi-asserted-by":"crossref","first-page":"e91020","DOI":"10.1172\/jci.insight.91020","article-title":"TLR7\/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth","volume":"2","author":"Dowling","year":"2017","journal-title":"Jci Insight."},{"key":"10.1016\/j.addr.2021.05.013_b1005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4049\/immunohorizons.1700063","article-title":"Recent advances in the discovery and delivery of TLR7\/8 agonists as vaccine adjuvants","volume":"2","author":"Dowling","year":"2018","journal-title":"Immunohorizons"},{"key":"10.1016\/j.addr.2021.05.013_b1010","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad6663","article-title":"TLR-7 activation enhances IL-22\u2013mediated colonization resistance against vancomycin-resistant enterococcus","volume":"8","author":"Abt","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2021.05.013_b1015","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2174\/187152812803589967","article-title":"The therapeutic potential of toll-like receptor 7 stimulation in Asthma","volume":"11","author":"Drake","year":"2012","journal-title":"Inflamm Allergy-Drug Targets."},{"key":"10.1016\/j.addr.2021.05.013_b1020","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000445324","article-title":"Toll-like receptor 7-targeted therapy in respiratory disease","volume":"43","author":"Lebold","year":"2016","journal-title":"Transfus Med. Hemoth."},{"key":"10.1016\/j.addr.2021.05.013_b1025","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejphar.2013.09.004","article-title":"Toll-like receptor (TLR) 7 decreases and TLR9 increases the airway responses in mice with established allergic inflammation","volume":"718","author":"Adner","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.addr.2021.05.013_b1030","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s12026-007-0083-2","article-title":"Immunotherapy of asthma using CpG oligodeoxynucleotides","volume":"39","author":"Kline","year":"2007","journal-title":"Immunol. Res."},{"key":"10.1016\/j.addr.2021.05.013_b1035","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/nrd1524","article-title":"New drugs for asthma","volume":"3","author":"Barnes","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2021.05.013_b1040","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1164\/rccm.201303-0442OC","article-title":"Toll-like receptor 7 rapidly relaxes human airways","volume":"188","author":"Drake","year":"2013","journal-title":"Am. J. Resp. Crit. Care."},{"key":"10.1016\/j.addr.2021.05.013_b1045","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/cea.12974","article-title":"Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: a randomized trial","volume":"47","author":"Ellis","year":"2017","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.addr.2021.05.013_b1050","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1021\/acs.jmedchem.5b01647","article-title":"Discovery of 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a highly potent and selective intranasal toll-like receptor 7 agonist for the treatment of asthma","volume":"59","author":"Biggadike","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b1055","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1476-5381.2011.01790.x","article-title":"Biological characterization of a novel class of toll-like receptor 7 agonists designed to have reduced systemic activity","volume":"166","author":"Biffen","year":"2012","journal-title":"Brit. J. Pharmacol."},{"key":"10.1016\/j.addr.2021.05.013_b1060","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12931-019-1252-2","article-title":"Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study","volume":"20","author":"Leaker","year":"2019","journal-title":"Respir. Res."},{"key":"10.1016\/j.addr.2021.05.013_b1065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/iid3.91","article-title":"VTX-1463, a novel TLR-8 agonist, attenuates nasal congestion after ragweed challenge in sensitized beagle dogs","volume":"4","author":"Royer","year":"2015","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.addr.2021.05.013_b1070","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1517\/13543784.2011.583237","article-title":"VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis","volume":"20","author":"Horak","year":"2011","journal-title":"Expert Opin. Inv. Drug."},{"key":"10.1016\/j.addr.2021.05.013_b1075","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/ni1006-1029","article-title":"On regulation of phagosome maturation and antigen presentation","volume":"7","author":"Blander","year":"2006","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b1080","doi-asserted-by":"crossref","first-page":"7676","DOI":"10.4049\/jimmunol.174.12.7676","article-title":"Immunization with HIV-1 gag protein conjugated to a TLR7\/8 agonist results in the generation of HIV-1 gag-specific Th1 and CD8+ T cell responses","volume":"174","author":"Wille-Reece","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b1085","doi-asserted-by":"crossref","first-page":"15190","DOI":"10.1073\/pnas.0507484102","article-title":"HIV Gag protein conjugated to a Toll-like receptor 7\/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates","volume":"102","author":"Wille-Reece","year":"2005","journal-title":"Proc. Natl. Acad Sci."},{"key":"10.1016\/j.addr.2021.05.013_b1090","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1172\/JCI45416","article-title":"Protective T cell immunity in mice following protein-TLR7\/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets","volume":"121","author":"Kastenm\u00fcller","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"185","key":"10.1016\/j.addr.2021.05.013_b1095","first-page":"4602","article-title":"The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity","volume":"1950","author":"Oh","year":"2010","journal-title":"J Immunol. Baltim. Md."},{"key":"10.1016\/j.addr.2021.05.013_b1100","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.virol.2013.07.028","article-title":"Chemical cross-linking of HIV-1 Env for direct TLR7\/8 ligand conjugation compromises recognition of conserved antigenic determinants","volume":"446","author":"Feng","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.addr.2021.05.013_b1105","first-page":"310","article-title":"Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model","volume":"87","author":"Vecchi","year":"2014","journal-title":"Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft F\u00fcr Pharmazeutische Verfahrenstechnik E"},{"issue":"197","key":"10.1016\/j.addr.2021.05.013_b1110","first-page":"555","article-title":"A novel R848-conjugated inactivated influenza virus vaccine is efficacious and safe in a neonate nonhuman primate model","volume":"1950","author":"Holbrook","year":"2016","journal-title":"J. Immunol. Baltim. Md."},{"key":"10.1016\/j.addr.2021.05.013_b1115","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/imm.12845","article-title":"An R848 adjuvanted influenza vaccine promotes early activation of B cells in the draining lymph nodes of non-human primate neonates","volume":"153","author":"Holbrook","year":"2018","journal-title":"Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b1120","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.1016\/j.vaccine.2017.09.054","article-title":"Adjuvanting an inactivated influenza vaccine with conjugated R848 improves the level of antibody present at 6months in a nonhuman primate neonate model","volume":"35","author":"Holbrook","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.05.013_b1125","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.vaccine.2018.01.035","article-title":"The choice of linker for conjugating R848 to inactivated influenza virus determines the stimulatory capacity for innate immune cells","volume":"36","author":"Westcott","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.05.013_b1130","first-page":"1","article-title":"Peptide\u2013TLR-7\/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens","author":"Lynn","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2021.05.013_b1135","first-page":"1","article-title":"Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells","author":"Baharom","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b1140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41563-018-0256-5","article-title":"Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity","volume":"18","author":"Wilson","year":"2019","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2021.05.013_b1145","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/nbt.3371","article-title":"In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity","volume":"33","author":"Lynn","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2021.05.013_b1150","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1021\/acs.biomac.8b01473","article-title":"Impact of polymer-TLR-7\/8 agonist (adjuvant) morphology on the potency and mechanism of CD8 T cell induction","volume":"20","author":"Lynn","year":"2019","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2021.05.013_b1155","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1600816113","article-title":"pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation","volume":"113","author":"Nuhn","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2021.05.013_b1160","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.biomaterials.2018.03.026","article-title":"Potent anti-viral vaccine adjuvant based on pH-degradable nanogels with covalently linked small molecule imidazoquinoline TLR7\/8 agonist","volume":"178","author":"Nuhn","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2021.05.013_b1165","doi-asserted-by":"crossref","first-page":"15390","DOI":"10.1002\/anie.201905687","article-title":"Potent lymphatic translocation and spatial control over innate immune activation by polymer-lipid amphiphile conjugates of small-molecule TLR7\/8 agonists","volume":"58","author":"Vrieze","year":"2019","journal-title":"Angewandte Chemie Int. Ed."},{"key":"10.1016\/j.addr.2021.05.013_b1170","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1021\/acs.bioconjchem.8b00386","article-title":"Hyaluronic acid conjugates of TLR7\/8 agonists for targeted delivery to secondary lymphoid tissue","volume":"29","author":"Yoo","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b1175","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.vaccine.2014.02.027","article-title":"Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release","volume":"32","author":"Ilyinskii","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.05.013_b1180","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1021\/acs.bioconjchem.6b00277","article-title":"Covalent conjugation of small-molecule adjuvants to nanoparticles induces robust cytotoxic T cell responses via DC activation","volume":"27","author":"Kim","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b1185","doi-asserted-by":"crossref","first-page":"2000081","DOI":"10.1002\/adtp.202000081","article-title":"Enhanced humoral immune response by high density TLR agonist presentation on hyperbranched polymers","author":"Liong","year":"2021","journal-title":"Adv Ther."},{"key":"10.1016\/j.addr.2021.05.013_b1190","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009980","article-title":"Rational design of small molecules as vaccine adjuvants","volume":"6","author":"Wu","year":"2014","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.addr.2021.05.013_b1195","doi-asserted-by":"crossref","first-page":"29063","DOI":"10.1038\/srep29063","article-title":"Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines","volume":"6","author":"Buonsanti","year":"2016","journal-title":"Sci. Rep-Uk."},{"key":"10.1016\/j.addr.2021.05.013_b1200","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1073\/pnas.1424924112","article-title":"Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus","volume":"112","author":"Bagnoli","year":"2015","journal-title":"P. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.addr.2021.05.013_b1205","doi-asserted-by":"crossref","first-page":"e0147767","DOI":"10.1371\/journal.pone.0147767","article-title":"One dose of staphylococcus aureus 4C-staph vaccine formulated with a novel TLR7-dependent adjuvant rapidly protects mice through antibodies, effector CD4+ T cells, and IL-17A","volume":"11","author":"Mancini","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2021.05.013_b1210","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1016\/j.vaccine.2017.08.009","article-title":"Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model","volume":"35","author":"Misiak","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.05.013_b1215","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.xphs.2018.01.024","article-title":"The preparation and physico-chemical characterization of aluminum hydroxide\/TLR7a, a novel vaccine adjuvant comprising a small molecule adsorbed to aluminum hydroxide","volume":"107","author":"Malyala","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2021.05.013_b1220","doi-asserted-by":"crossref","first-page":"108275","DOI":"10.1016\/j.clim.2019.108275","article-title":"Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine","volume":"209","author":"Gonzalez-Lopez","year":"2019","journal-title":"Clin Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b1225","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jconrel.2016.11.011","article-title":"Adsorption of a synthetic TLR7\/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: a formulation approach","volume":"244","author":"Fox","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.05.013_b1230","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/bloodadvances.2017011411","article-title":"Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs","volume":"1","author":"Francica","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.addr.2021.05.013_b1235","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm.4105","article-title":"Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition","volume":"22","author":"Vaccari","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2021.05.013_b1240","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.vaccine.2005.09.046","article-title":"A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens","volume":"24","author":"Singh","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.05.013_b1245","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/s41467-021-21639-w","article-title":"Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques","volume":"12","author":"Yadav","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2021.05.013_b1250","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial","author":"Ella","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2021.05.013_b1255","doi-asserted-by":"crossref","first-page":"102298","DOI":"10.1016\/j.isci.2021.102298","article-title":"Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation","volume":"24","author":"Ganneru","year":"2021","journal-title":"Iscience"},{"key":"10.1016\/j.addr.2021.05.013_b1260","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial","author":"Ella","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2021.05.013_b1265","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00094-3","article-title":"Adjuvantation helps to optimise COVID-19 vaccine candidate","author":"Li","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2021.05.013_b1270","article-title":"Sterilizing immunity against SARS-CoV-2 infection in mice by a single-shot and lipid amphiphile imidazoquinoline TLR7\/8 agonist-adjuvanted recombinant spike protein vaccine","author":"Jangra","year":"2021","journal-title":"Angewandte Chemie Int. Ed."},{"key":"10.1016\/j.addr.2021.05.013_b1275","doi-asserted-by":"crossref","first-page":"e126047","DOI":"10.1172\/jci.insight.126047","article-title":"Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques","volume":"4","author":"Petitdemange","year":"2019","journal-title":"Jci Insight."},{"key":"10.1016\/j.addr.2021.05.013_b1280","first-page":"1","article-title":"T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers","author":"Arunachalam","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2021.05.013_b1285","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jaci.2012.02.042","article-title":"Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways","volume":"130","author":"Philbin","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b1290","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1021\/mp400092y","article-title":"Multifunctional PLGA-based nanoparticles encapsulating simultaneously hydrophilic antigen and hydrophobic immunomodulator for mucosal immunization","volume":"10","author":"Primard","year":"2013","journal-title":"Mol. Pharmaceut."},{"key":"10.1016\/j.addr.2021.05.013_b1295","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.biomaterials.2018.02.034","article-title":"Polymeric nanoparticles encapsulating novel TLR7\/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy","volume":"164","author":"Kim","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2021.05.013_b1300","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1021\/acsbiomaterials.6b00408","article-title":"Fatty acid-mimetic micelles for dual delivery of antigens and imidazoquinoline adjuvants","volume":"3","author":"Sevimli","year":"2017","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.addr.2021.05.013_b1305","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jaci.2016.12.985","article-title":"Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses","volume":"140","author":"Dowling","year":"2017","journal-title":"J. Allergy Clin. Immun."},{"key":"10.1016\/j.addr.2021.05.013_b1310","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jconrel.2013.09.012","article-title":"Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: a needle-free vaccination strategy","volume":"172","author":"Vicente","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.05.013_b1315","doi-asserted-by":"crossref","first-page":"9702","DOI":"10.1021\/acsnano.8b04146","article-title":"Enhanced cancer vaccination by in situ nanomicelle-generating dissolving microneedles","volume":"12","author":"Kim","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2021.05.013_b1320","doi-asserted-by":"crossref","first-page":"10393","DOI":"10.1039\/D1RA00747E","article-title":"Dissolving microneedles delivering cancer cell membrane coated nanoparticles for cancer immunotherapy","volume":"11","author":"Park","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.addr.2021.05.013_b1325","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1021\/bc1004813","article-title":"Synthesis and characterization of PEGylated toll like receptor 7 ligands","volume":"22","author":"Chan","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b1330","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1021\/acschembio.6b00895","article-title":"Immune response modulation of conjugated agonists with changing linker length","volume":"11","author":"Ryu","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.addr.2021.05.013_b1335","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1073\/pnas.0611624104","article-title":"Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand","volume":"104","author":"Wu","year":"2007","journal-title":"Proc. Natl. Acad Sci."},{"key":"10.1016\/j.addr.2021.05.013_b1340","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1021\/acs.bioconjchem.5b00285","article-title":"Enhancement of the immunostimulatory activity of a TLR7 ligand by conjugation to polysaccharides","volume":"26","author":"Shinchi","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b1345","doi-asserted-by":"crossref","first-page":"201803281","DOI":"10.1073\/pnas.1803281115","article-title":"Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist","volume":"115","author":"Hosoya","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2021.05.013_b1350","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1021\/mp3005098","article-title":"Electrospray encapsulation of toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis","volume":"10","author":"Duong","year":"2013","journal-title":"Mol. Pharmaceut."},{"key":"10.1016\/j.addr.2021.05.013_b1355","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","article-title":"TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy","volume":"2","author":"Rodell","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.addr.2021.05.013_b1360","doi-asserted-by":"crossref","first-page":"8426","DOI":"10.7150\/thno.35434","article-title":"Development of adamantane-conjugated TLR7\/8 agonists for supramolecular delivery and cancer immunotherapy","volume":"9","author":"Rodell","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2021.05.013_b1365","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2019.12.007","article-title":"Myeloid cell-targeted nanocarriers efficiently inhibit cellular inhibitor of apoptosis for cancer immunotherapy","volume":"27","author":"Koch","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.addr.2021.05.013_b1370","doi-asserted-by":"crossref","first-page":"eaba5542","DOI":"10.1126\/sciadv.aba5542","article-title":"High-capacity poly(2-oxazoline) formulation of TLR 7\/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma","volume":"6","author":"Vinod","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2021.05.013_b1375","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.biomaterials.2018.10.031","article-title":"Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation","volume":"190","author":"Mottas","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2021.05.013_b1380","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1016\/j.biomaterials.2012.04.060","article-title":"Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes","volume":"33","author":"Scott","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2021.05.013_b1385","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1021\/acsabm.9b00399","article-title":"Oxidation-sensitive dextran-based polymer with improved processability through stable boronic ester groups","volume":"2","author":"Manaster","year":"2019","journal-title":"Acs Appl. Bio. Mater."},{"key":"10.1016\/j.addr.2021.05.013_b1390","doi-asserted-by":"crossref","first-page":"10823","DOI":"10.1021\/ja412314j","article-title":"Stimulation of innate immune cells by light-activated TLR7\/8 agonists","volume":"136","author":"Ryu","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2021.05.013_b1395","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/cmdc.201600443","article-title":"An enzyme-directed imidazoquinoline for cancer immunotherapy","volume":"11","author":"Hantho","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.addr.2021.05.013_b1400","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41401-020-0432-4","article-title":"Comparing the immunogenicity of glycosidase-directed resiquimod prodrugs mediated by cancer cell metabolism","volume":"41","author":"Ryan","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.addr.2021.05.013_b1405","article-title":"Potent and prolonged innate immune activation by enzyme-responsive imidazoquinoline TLR7\/8 agonist prodrug vesicles","author":"Wang","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2021.05.013_b1410","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41467-017-01830-8","article-title":"T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity","volume":"8","author":"Schmid","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2021.05.013_b1415","doi-asserted-by":"crossref","first-page":"6836","DOI":"10.1182\/blood-2011-07-367615","article-title":"Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity","volume":"118","author":"Tacken","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.addr.2021.05.013_b1420","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/acs.bioconjchem.5b00302","article-title":"Targeted activation of toll-like receptors: conjugation of a toll-like receptor 7 agonist to a monoclonal antibody maintains antigen binding and specificity","volume":"26","author":"Gadd","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b1425","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.actbio.2017.01.072","article-title":"Delivery of TLR7 agonist to monocytes and dendritic cells by DCIR targeted liposomes induces robust production of anti-cancer cytokines","volume":"53","author":"Klauber","year":"2017","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2021.05.013_b1430","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1517\/17425247.2015.1009444","article-title":"Monocyte targeting and activation by cationic liposomes formulated with a TLR7 agonist","volume":"12","author":"Johansen","year":"2015","journal-title":"Expert Opin. Drug. Del."},{"key":"10.1016\/j.addr.2021.05.013_b1435","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/anie.201610209","article-title":"Non-viral CRISPR\/cas gene editing in vitro and in vivo enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA","volume":"56","author":"Miller","year":"2016","journal-title":"Angewandte Chemie Int. Ed. Engl."},{"key":"10.1016\/j.addr.2021.05.013_b1440","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2021.05.013_b1445","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4049\/jimmunol.1601145","article-title":"Intratumoral delivery of immunotherapy\u2014act locally, think globally","volume":"198","author":"Aznar","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b1450","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1517\/14656566.2014.967682","article-title":"Intralesional therapy for metastatic melanoma","volume":"15","author":"Sloot","year":"2014","journal-title":"Expert. Opin. Pharmaco."},{"key":"10.1016\/j.addr.2021.05.013_b1455","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy","volume":"4","author":"Rehman","year":"2016","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.addr.2021.05.013_b1460","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","article-title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","volume":"25","author":"Hammerich","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2021.05.013_b1465","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.9025","article-title":"Systemic antitumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma","volume":"32","author":"Daud","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2021.05.013_b1470","article-title":"Intratumoral Immunotherapy for Early-stage Solid Tumors","author":"Hong","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"1","key":"10.1016\/j.addr.2021.05.013_b9000","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s40425-019-0724-8","article-title":"Intratumoral immunotherapy with TLR7\/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies","volume":"7","author":"Mullins","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.addr.2021.05.013_b1475","doi-asserted-by":"crossref","unstructured":"S. Gupta, J. Grilley-Olson, D. Hong, A. Marabelle, P. Munster, R. Aggarwal, S. Aspeslagh, R.G. Dixon, M. Patel, V. Subbiah, C. Morehouse, Y. Wu, J. Zha, L. Tseng, Z.A. Cooper, S. Morris, J. Brody, Abstract CT091: Safety and pharmacodynamic activity of MEDI9197, a TLR 7\/8 agonist, administered intratumorally in subjects with solid tumors, 2017, CT091\u2013CT091. https:\/\/doi.org\/10.1158\/1538-7445.am2017-ct091.","DOI":"10.1158\/1538-7445.AM2017-CT091"},{"key":"10.1016\/j.addr.2021.05.013_b1480","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.xphs.2017.04.041","article-title":"Thermosensitive gel-based formulation for intratumoral delivery of toll-like receptor 7\/8 dual agonist, MEDI9197","volume":"106","author":"Fakhari","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2021.05.013_b1485","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1016\/j.vaccine.2011.05.061","article-title":"Vaccine adjuvant activity of 3M\u2013052: an imidazoquinoline designed for local activity without systemic cytokine induction","volume":"29","author":"Smirnov","year":"2011","journal-title":"Vaccine."},{"key":"10.1016\/j.addr.2021.05.013_b1490","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1021\/acs.jmedchem.6b00489","article-title":"Incorporation of phosphonate into benzonaphthyridine toll-like receptor 7 agonists for adsorption to aluminum hydroxide","volume":"59","author":"Cortez","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2021.05.013_b1495","unstructured":"Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03301896."},{"key":"10.1016\/j.addr.2021.05.013_b1500","unstructured":"B. Georges, Immunogenic Compound, US10,434,183 B2, 2019. https:\/\/patentimages.storage.googleapis.com\/72\/16\/72\/6d37b4c964d73a\/US10434183.pdf."},{"key":"10.1016\/j.addr.2021.05.013_b1505","first-page":"283","article-title":"Intratumoral delivery of TransConTM TLR7\/8 agonist provides potent anti-tumor activity as a monotherapy and in combination with IL-2 while minimizing systemic cytokine induction","volume":"7","author":"Zuniga","year":"2019","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.addr.2021.05.013_b1510","doi-asserted-by":"crossref","first-page":"1803397","DOI":"10.1002\/adma.201803397","article-title":"Nanoparticle-conjugate TLR7\/8 agonist localized immunotherapy provokes safe antitumoral responses","volume":"30","author":"Nuhn","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2021.05.013_b1515","doi-asserted-by":"crossref","first-page":"12671","DOI":"10.1021\/acsnano.9b04207","article-title":"Lyophilizable and multifaceted toll-like receptor 7\/8 agonist-loaded nanoemulsion for the reprogramming of tumor microenvironments and enhanced cancer immunotherapy","volume":"13","author":"Kim","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2021.05.013_b1520","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2019.06.003","article-title":"Formulation and preclinical evaluation of a toll-like receptor 7\/8 agonist as an anti-tumoral immunomodulator","volume":"306","author":"Lu","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.05.013_b1525","doi-asserted-by":"crossref","DOI":"10.1039\/D0SC02611E","article-title":"ABC triblock bottlebrush copolymer-based injectable hydrogels: design, synthesis, and application to expanding the therapeutic index of cancer immunochemotherapy","author":"Vohidov","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.addr.2021.05.013_b1530","doi-asserted-by":"crossref","DOI":"10.1021\/acs.biomac.0c00205","article-title":"Control over imidazoquinoline immune stimulation by pH-degradable poly(norbornene) nanogels","volume":"21","author":"Kockelmann","year":"2020","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2021.05.013_b1535","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/s41467-021-22311-z","article-title":"Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors","volume":"12","author":"Bahmani","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2021.05.013_b1540","doi-asserted-by":"crossref","first-page":"eaar1916","DOI":"10.1126\/scitranslmed.aar1916","article-title":"Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases","volume":"10","author":"Park","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2021.05.013_b1545","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc3973","article-title":"Evolving synergistic combinations of targeted immunotherapies to combat cancer","volume":"15","author":"Melero","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2021.05.013_b1550","doi-asserted-by":"crossref","first-page":"eabd8636","DOI":"10.1126\/scitranslmed.abd8636","article-title":"Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses","volume":"13","author":"Lo","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2021.05.013_b1555","doi-asserted-by":"crossref","first-page":"eaax2282","DOI":"10.1126\/scitranslmed.aax2282","article-title":"Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade","volume":"12","author":"Wang","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2021.05.013_b1560","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1084\/jem.20051720","article-title":"Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity","volume":"203","author":"Querec","year":"2006","journal-title":"J Exp Medicine."},{"key":"10.1016\/j.addr.2021.05.013_b1565","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/ni1223","article-title":"Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1\u2013polarizing program in dendritic cells","volume":"6","author":"Napolitani","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b1570","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1400478111","article-title":"Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants","volume":"111","author":"Maisonneuve","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2021.05.013_b1575","doi-asserted-by":"crossref","unstructured":"Shekarian T, Valsesia-Wittmann S, Brody J, Michallet MC, Depil S, Caux C, Marabelle, Pattern recognition receptors: immune targets to enhance cancer immunotherapy, 2017. https:\/\/doi.org\/10.1093\/annonc\/mdx179.","DOI":"10.1093\/annonc\/mdz225"},{"key":"10.1016\/j.addr.2021.05.013_b1580","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature09737","article-title":"Programming the magnitude and persistence of antibody responses with innate immunity","volume":"470","author":"Kasturi","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.05.013_b1585","doi-asserted-by":"crossref","first-page":"e01844","DOI":"10.1128\/JVI.01844-16","article-title":"Adjuvanting a simian immunodeficiency virus vaccine with toll-like receptor ligands encapsulated in nanoparticles induces persistent antibody responses and enhanced protection in TRIM5\u03b1 restrictive macaques","volume":"91","author":"Kasturi","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.05.013_b1590","doi-asserted-by":"crossref","first-page":"eabb1025","DOI":"10.1126\/sciimmunol.abb1025","article-title":"3M\u2013052, a synthetic TLR-7\/8 agonist, induces durable HIV-1 envelope\u2013specific plasma cells and humoral immunity in nonhuman primates","volume":"5","author":"Kasturi","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b1595","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1477-3155-12-17","article-title":"A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7","volume":"12","author":"Fox","year":"2014","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2021.05.013_b1600","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jconrel.2012.10.020","article-title":"Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses","volume":"165","author":"Rizwan","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.05.013_b1605","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.03337-14","article-title":"Synthetic toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses","volume":"89","author":"Goff","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.05.013_b1610","doi-asserted-by":"crossref","first-page":"e0148984","DOI":"10.1371\/journal.pone.0148984","article-title":"TLR4 and TLR7\/8 adjuvant combinations generate different vaccine antigen-specific immune outcomes in minipigs when administered via the ID or IN routes","volume":"11","author":"McKay","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2021.05.013_b1615","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1128\/JVI.03309-13","article-title":"Toll-like receptor 7\/8 (TLR7\/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques","volume":"88","author":"Moody","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.05.013_b1620","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1038\/s41598-017-02804-y","article-title":"Combinatorial delivery of dual and triple TLR agonists via polymeric pathogen-like particles synergistically enhances innate and adaptive immune responses","volume":"7","author":"Madan-Lala","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.05.013_b1625","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1021\/acscentsci.5b00274","article-title":"Modulation of innate immune responses via covalently linked TLR agonists","volume":"1","author":"Tom","year":"2015","journal-title":"Acs Central Sci."},{"key":"10.1016\/j.addr.2021.05.013_b1630","doi-asserted-by":"crossref","DOI":"10.1021\/acschembio.0c00924","article-title":"Receptor-ligand kinetics influence the mechanism of action of covalently linked TLR ligands","author":"Kimani","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.addr.2021.05.013_b1635","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.4049\/jimmunol.178.2.1164","article-title":"MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists","volume":"178","author":"Bagchi","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b1640","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1158\/0008-5472.CAN-04-0063","article-title":"Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity","volume":"64","author":"Whitmore","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2021.05.013_b1645","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/acscentsci.8b00823","article-title":"Linked toll-like receptor triagonists stimulate distinct, combination-dependent innate immune responses","volume":"5","author":"Albin","year":"2019","journal-title":"Acs Central Sci."},{"key":"10.1016\/j.addr.2021.05.013_b1650","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1021\/acscentsci.0c01001","article-title":"Pathogen-like nanoassemblies of covalently linked TLR agonists enhance CD8 and NK cell-mediated antitumor immunity","volume":"6","author":"Manna","year":"2020","journal-title":"Acs Central Sci."},{"key":"10.1016\/j.addr.2021.05.013_b1655","doi-asserted-by":"crossref","first-page":"eabd4235","DOI":"10.1126\/sciadv.abd4235","article-title":"TRAF6-IRF5 kinetics, TRIF, and biophysical factors drive synergistic innate responses to particle-mediated MPLA-CpG co-presentation","volume":"7","author":"Pradhan","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2021.05.013_b1660","doi-asserted-by":"crossref","first-page":"eaaw6071","DOI":"10.1126\/sciadv.aaw6071","article-title":"A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer","volume":"6","author":"Ni","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2021.05.013_b1665","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jconrel.2020.10.060","article-title":"TLR7 and RIG-I dual-adjuvant loaded nanoparticles drive broadened and synergistic responses in dendritic cells in vitro and generate unique cellular immune responses in influenza vaccination","volume":"330","author":"Toy","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.05.013_b1670","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2012-05-432393","article-title":"Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma","volume":"121","author":"Dovedi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.addr.2021.05.013_b1675","doi-asserted-by":"crossref","first-page":"eaan4488","DOI":"10.1126\/scitranslmed.aan4488","article-title":"Eradication of spontaneous malignancy by local immunotherapy","volume":"10","author":"Sagiv-Barfi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2021.05.013_b1680","doi-asserted-by":"crossref","first-page":"1900200","DOI":"10.1002\/adtp.201900200","article-title":"Immunostimulatory TLR7 agonist-nanoparticles together with checkpoint blockade for effective cancer immunotherapy","volume":"3","author":"Huang","year":"2020","journal-title":"Adv Ther."},{"key":"10.1016\/j.addr.2021.05.013_b1685","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93397","article-title":"Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer","volume":"2","author":"Sato-Kaneko","year":"2017","journal-title":"JCI Insight."},{"key":"10.1016\/j.addr.2021.05.013_b1690","doi-asserted-by":"crossref","first-page":"13301","DOI":"10.18632\/oncotarget.24327","article-title":"Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy","volume":"9","author":"Nishii","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.addr.2021.05.013_b1695","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1021\/acs.biomac.0c00812","article-title":"Nanoparticles presenting potent TLR7\/8 agonists enhance anti-PD-L1 immunotherapy in cancer treatment","volume":"21","author":"Smith","year":"2020","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2021.05.013_b1700","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.0c00271","article-title":"TLR7\/8 agonist-loaded nanoparticles augment NK cell-mediated antibody-based cancer immunotherapy","volume":"17","author":"Kim","year":"2020","journal-title":"Mol. Pharmaceut."},{"key":"10.1016\/j.addr.2021.05.013_b1705","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/CMR.0b013e328340ce6c","article-title":"Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2","volume":"21","author":"Hayashi","year":"2011","journal-title":"Melanoma Res."},{"key":"10.1016\/j.addr.2021.05.013_b1710","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.biomaterials.2013.10.009","article-title":"Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells","volume":"35","author":"Heo","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2021.05.013_b1715","doi-asserted-by":"crossref","first-page":"119417","DOI":"10.1016\/j.biomaterials.2019.119417","article-title":"Co-delivery of immunomodulators in biodegradable nanoparticles improves therapeutic efficacy of cancer vaccines","volume":"220","author":"Silva","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2021.05.013_b1720","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1038\/s41598-021-83005-6","article-title":"Novel TLR 7\/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC)","volume":"11","author":"Khanna","year":"2021","journal-title":"Sci. Rep-Uk."},{"key":"10.1016\/j.addr.2021.05.013_b1725","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s42003-021-01800-3","article-title":"Enhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors","volume":"4","author":"D\u00edaz-Carballo","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.addr.2021.05.013_b1730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2018.1526250","article-title":"Trial watch: toll-like receptor agonists in cancer immunotherapy","volume":"7","author":"Smith","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.addr.2021.05.013_b1735","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.it.2009.07.009","article-title":"Endotoxin tolerance: new mechanisms, molecules and clinical significance","volume":"30","author":"Biswas","year":"2009","journal-title":"Trends Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b1740","doi-asserted-by":"crossref","first-page":"19438","DOI":"10.1073\/pnas.1007816107","article-title":"IFN-\u03b3 abrogates endotoxin tolerance by facilitating Toll-like receptor-induced chromatin remodeling","volume":"107","author":"Chen","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2021.05.013_b1745","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1073\/pnas.1109173109","article-title":"A tolerogenic role for Toll-like receptor 9 is revealed by B-cell interaction with DNA complexes expressed on apoptotic cells","volume":"109","author":"Miles","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2021.05.013_b1750","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.immuni.2011.12.017","article-title":"The circadian clock controls toll-like receptor 9-mediated innate and adaptive immunity","volume":"36","author":"Silver","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2021.05.013_b1755","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.it.2012.05.002","article-title":"Dissecting negative regulation of Toll-like receptor signaling","volume":"33","author":"Kondo","year":"2012","journal-title":"Trends Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b1760","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1158\/0008-5472.CAN-06-2381","article-title":"Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents","volume":"67","author":"Shi","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2021.05.013_b1765","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00262-015-1730-4","article-title":"TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice","volume":"64","author":"Koga-Yamakawa","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.addr.2021.05.013_b1770","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1073\/pnas.0813037106","article-title":"Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7","volume":"106","author":"Hayashi","year":"2009","journal-title":"P. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.addr.2021.05.013_b1775","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.4049\/jimmunol.1200624","article-title":"Type I IFN receptor and the B cell antigen receptor regulate TLR7 responses via distinct molecular mechanisms","volume":"189","author":"Poovassery","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.05.013_b1780","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.bbi.2019.09.004","article-title":"Persistent Toll-like receptor 7 stimulation induces behavioral and molecular innate immune tolerance","volume":"82","author":"Michaelis","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.addr.2021.05.013_b1785","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/0008-5472.CAN-10-3903","article-title":"Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance","volume":"71","author":"Bourquin","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2021.05.013_b1790","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/cpt.157","article-title":"Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: use of translational biomarkers to guide dosing and confirm target engagement","volume":"98","author":"Tsitoura","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2021.05.013_b1795","doi-asserted-by":"crossref","first-page":"e00579","DOI":"10.1016\/j.heliyon.2018.e00579","article-title":"Daily oscillations in expression and responsiveness of Toll-like receptors in splenic immune cells","volume":"4","author":"Silver","year":"2018","journal-title":"Heliyon"},{"key":"10.1016\/j.addr.2021.05.013_b1800","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1073\/pnas.1915773117","article-title":"Circadian control of interferon-sensitive gene expression in murine skin","volume":"117","author":"Greenberg","year":"2020","journal-title":"Proc. Natl. Acad. Sci."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21001770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21001770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:08:16Z","timestamp":1759208896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X21001770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":361,"alternative-id":["S0169409X21001770"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2021.05.013","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of Toll-like receptor 7\/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2021.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113803"}}